Nuclear Medicine and Molecular Imaging, Imaging Pathology, KU Leuven, Leuven, Belgium.
Neuropsychiatry, Department of Neurosciences, Leuven Brain Institute, KU Leuven, Leuven, Belgium.
Mol Psychiatry. 2022 Oct;27(10):4244-4251. doi: 10.1038/s41380-022-01672-x. Epub 2022 Jul 6.
Next to amyloid and tau, synaptic loss is a key pathological hallmark in Alzheimer's disease, closely related to cognitive dysfunction and neurodegeneration. Tau is thought to cause synaptic loss, but this has not been experimentally verified in vivo. In a 2-year follow-up study, dual tracer PET-MR was performed in 12 amnestic MCI patients using F-MK-6240 for tau and C-UCB-J for SV2A as a proxy for synaptic density. Tau already accumulated in the neocortex at baseline with progression in Braak V/VI at follow-up. While synaptic loss was limited to limbic regions at baseline, it followed the specific tau pattern to stage IV/V regions two years later, indicating that tau spread might drive synaptic vulnerability. Moreover, synaptic density changes correlated to changes in cognitive function. This study shows for the first time in vivo that synaptic loss regionally follows tau accumulation after two years, providing a disease-modifying window of opportunity for (combined) tau-targeting therapies.
除了淀粉样蛋白和 tau 蛋白,突触丢失是阿尔茨海默病的一个关键病理标志,与认知功能障碍和神经退行性变密切相关。tau 蛋白被认为会导致突触丢失,但这在体内尚未得到实验验证。在一项为期 2 年的随访研究中,12 名遗忘型轻度认知障碍患者使用 F-MK-6240 进行 tau 双示踪 PET-MR 检查,使用 C-UCB-J 作为突触密度的替代物进行 SV2A 双示踪 PET-MR 检查。tau 蛋白在基线时已经在前脑皮层积累,并在随访时进展到 Braak V/VI 阶段。虽然在基线时突触丢失仅限于边缘区域,但两年后它沿着特定的 tau 蛋白模式发展到第四/五阶段,表明 tau 蛋白的扩散可能导致突触脆弱性。此外,突触密度的变化与认知功能的变化相关。这项研究首次在体内显示,突触丢失在两年后区域性地跟随 tau 蛋白的积累,为(联合)tau 靶向治疗提供了一个疾病修饰的机会窗口。